Boundless Bio (BOLD) Share-based Compensation (2023 - 2026)
Boundless Bio (BOLD) posted quarterly Share-based Compensation of $1.4 million for Q1 2026, down 23.71% year-over-year from $1.8 million in Q1 2025, and up 2.93% quarter-over-quarter from $1.3 million in Q4 2025.
Boundless Bio (BOLD) Share-based Compensation (2023 - 2026) Analysis & Trends
Boundless Bio (BOLD) has reported Share-based Compensation for 4 consecutive years, with $1.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 23.71% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $6.2 million (down 22.44% YoY), while the FY2025 annual figure was $9.2 million, down 39.87% from the prior year.
- Share-based Compensation grew to $1.4 million in Q1 2026 per BOLD's latest filing, from $1.3 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $10.7 million in Q3 2025 and bottomed at -$2.1 million in Q4 2023.
- Historically, Share-based Compensation has averaged $1.9 million across 4 years, with a median of $1.4 million in 2026.
- On a YoY basis, Share-based Compensation climbed as much as 423.23% in 2025 and fell as far as 33.67% in 2025.
- Boundless Bio's Share-based Compensation stood at -$2.1 million in 2023, then soared by 193.7% to $2.0 million in 2024, then tumbled by 33.67% to $1.3 million in 2025, then advanced by 2.93% to $1.4 million in 2026.
- Business Quant data shows BOLD's Share-based Compensation at $1.4 million in Q1 2026, $1.3 million in Q4 2025, and $10.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | - |
| 10 | Boundless Bio | 67.13 Mn | 67.13 Mn | - | 3.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.22 Mn |
| Jun 30, 2026 | 3.22 Mn |
| Mar 31, 2026 | 1.37 Mn |
| Mar 31, 2026 | 1.37 Mn |
| Dec 31, 2025 | 1.33 Mn |
| Dec 31, 2025 | 1.33 Mn |
| Sep 30, 2025 | 10.70 Mn |
| Sep 30, 2025 | 10.70 Mn |
| Jun 30, 2025 | 1.69 Mn |
| Jun 30, 2025 | 1.69 Mn |
| Mar 31, 2025 | 1.80 Mn |
| Mar 31, 2025 | 1.80 Mn |
| Dec 31, 2024 | 2.01 Mn |
| Dec 31, 2024 | 2.01 Mn |
| Sep 30, 2024 | 2.05 Mn |
| Sep 30, 2024 | 2.05 Mn |
| Jun 30, 2024 | 2.14 Mn |
| Jun 30, 2024 | 2.14 Mn |
| Mar 31, 2024 | 1.33 Mn |
| Mar 31, 2024 | 1.33 Mn |